Close Menu

NEW YORK (GenomeWeb) – Editas Medicine announced Monday that is has closed its initial public offering, raising $97.8 million in net proceeds, including the over-allotment option.

The Cambridge, Massachusetts-based gene editing firm sold 5.9 million shares at the public offering price of $16 per share as well as 885,000 additional shares issued to the underwriters, who fully exercised the over-allotment option.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The founder of MeTooSTEM, BethAnn McLaughlin, created a Twitter account purported to be that of an LGBTQ Native American professor at Arizona State University, the New York Times writes.

Novavax reports its candidate SARS-CoV-2 vaccine leads to immune responses, according to the Sydney Morning Herald.

Gene length is associated with lifespan in a comparative genomics study appearing in the Proceedings of the National Academy of Sciences that draws on the whale shark genome.

In Nucleic Acids Research this week: effort to annotate the rat transcriptome, web-based resource to characterize marine microbes, and more.